TORONTO, ON — April 16, 2002 — Health Canada has approved Plavix (clopidogrel bisulfate) for the prevention of ischemic events, myocardial infarction (heart attack), stroke and cardiovascular death in patients with acute coronary syndrome.
The new indication for Plavix is based on the conclusive and positive results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study, which was published in August 2001 in The New England Journal of Medicine(1).
In the CURE study of 12,562 patients with ACS, Plavix was compared to placebo, with both groups receiving standard therapy including aspirin. The study demonstrated that using Plavix significantly reduced the risk of heart attack, stroke or cardiovascular death by 20 percent (P=0.00009) in patients with mild heart attack or unstable angina.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!